Botanix Pharmaceuticals Limited (BOT) AI Stock Analysis

• Market Cap: AU$226.56M
• Dividend Yield: N/A
• Average Volume (3M): 8.47M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: 456.50%
• EPS Growth: -457.14%
• Country: AU
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 1,970,102,800
• 10 Day Avg. Volume: 7,344,780
• 30 Day Avg. Volume: 8,473,310
• PEG Ratio: -0.02
• Price to Book (P/B): 7.26
• Price to Sales (P/S): 101.98
• P/FCF Ratio: -7.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$1.12
• Price Target Upside: 833.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: AU$0.10 ▼(-14.17% Downside)

The score is held down primarily by weak financial performance driven by very large losses and heavy, worsening cash burn despite improved revenue and gross margin. Technicals remain soft with the stock below key longer-term moving averages and negative MACD, while valuation offers limited support given the negative P/E and lack of dividend data.

Positive Factors

Revenue rebound & positive gross margin

A sharp revenue rebound with a return to positive gross margin indicates improving product or commercial traction and better unit economics. If sustained, this supports scalability: incremental revenue can flow to the bottom line more efficiently, improving long-term profitability prospects as fixed costs are absorbed.

Focused dermatology/infectious-disease strategy

A clear strategic focus on dermatology and infectious disease builds domain expertise and enables targeted R&D and regulatory pathways. That specialization improves chances of successful clinical development, partnering and niche commercial leadership, creating durable competitive positioning over time.

Moderate leverage and equity cushion

Moderate debt levels and a meaningful equity buffer provide financial flexibility to fund near-term operations or raise additional capital without crippling leverage. This balance sheet structure reduces refinancing stress risk and supports continued R&D or commercialization activities over the medium term.

Negative Factors

Very large cash burn

Severe negative operating and free cash flows indicate the business is consuming cash far faster than it generates it, creating persistent funding needs. Over months this increases dependence on external financing, heightens dilution and execution risk, and pressures the firm's runway if revenues don't scale.

Large net loss and negative ROE

A very large net loss and deeply negative ROE reflect operations far from profitability, implying weak returns on invested capital. Persisting losses can erode shareholder value, necessitate repeated financings, and limit reinvestment, making long-term value creation uncertain absent clear path to sustained profits.

Very small employee base

A headcount of ~11 suggests limited internal capacity for simultaneous R&D, regulatory, and commercial execution. Long-term scaling, faster clinical programs or direct commercialization may require partnerships or significant hiring, adding costs and execution complexity that can constrain durable growth.

Botanix Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.

How the Company Makes Money

Botanix Pharmaceuticals Limited makes money through the development and commercialization of its dermatological products, primarily leveraging its proprietary Permetrex technology. The company's revenue model revolves around licensing agreements, partnerships, and collaborations with larger pharmaceutical companies, enabling them to bring their products to market. These collaborations often involve upfront payments, milestone payments based on the achievement of certain development or regulatory milestones, and royalties on future sales. Additionally, Botanix may generate revenue from the direct sale of its approved products to healthcare providers and patients.

Botanix Pharmaceuticals Limited Financial Statement Overview

Summary

Despite a sharp FY2025 revenue rebound and a return to positive gross margin, results remain dominated by a very large net loss and accelerating cash burn, implying continued dependence on external funding. Balance sheet leverage is moderate, but ROE is deeply negative due to losses.

Income Statement

Revenue rebounded sharply in FY2025 (up ~180% YoY to ~5.8m vs ~0.6m in FY2024) and gross margin turned positive (~35% vs deeply negative in FY2024). However, profitability remains very weak: the company is still heavily loss-making (FY2025 net loss ~86.4m), with extremely negative operating and net margins, indicating a cost base far above current revenue scale and limited near-term earnings visibility.

Balance Sheet

The balance sheet shows moderate leverage in FY2025, with debt of ~32.5m against equity of ~81.3m (debt-to-equity ~0.40). Assets (~129.1m) are supported by a meaningful equity cushion, but returns to shareholders are deeply negative (ROE ~-106% in FY2025) due to large losses, which is a key risk if losses persist and further funding is required.

Cash Flow

Cash generation is a major weakness: operating cash flow was materially negative in FY2025 (~-78.6m) and free cash flow was also negative (~-78.9m), reflecting heavy cash burn. Cash burn accelerated versus FY2024 operating cash outflow (~-8.1m) and FY2024 free cash outflow (~-26.1m), increasing financing dependence despite free cash flow roughly tracking net loss in FY2025.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.79M	5.79M	601.82K	914.97K	2.75M	6.89M
Gross Profit	2.02M	2.02M	-6.12M	-3.05M	-7.54M	315.80K
EBITDA	-80.65M	-80.65M	-15.25M	-12.63M	-15.74M	-10.06M
Net Income	-86.40M	-86.40M	-13.87M	-9.15M	-13.17M	-3.33M
Balance Sheet
Total Assets	129.10M	129.10M	112.46M	24.84M	14.04M	21.95M
Cash, Cash Equivalents and Short-Term Investments	64.97M	64.97M	79.31M	10.25M	7.29M	21.55M
Total Debt	32.51M	32.51M	0.00	0.00	122.41K	259.32K
Total Liabilities	47.80M	47.80M	3.73M	1.88M	5.89M	1.15M
Stockholders Equity	81.30M	81.30M	108.73M	22.95M	8.15M	20.80M
Cash Flow
Free Cash Flow	-78.87M	-78.87M	-26.13M	-19.13M	-14.11M	-2.98M
Operating Cash Flow	-78.58M	-78.58M	-8.13M	-12.07M	-11.18M	-2.97M
Investing Cash Flow	-1.05M	-1.05M	-18.00M	-7.05M	-2.92M	-8.28K
Financing Cash Flow	65.36M	65.36M	95.10M	22.03M	-152.41K	-125.50K

Botanix Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BOT, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.12, and below the 200-day MA of 0.20, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.86 is Neutral, neither overbought nor oversold. The STOCH value of 41.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BOT.

Botanix Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CUV	73 Outperform	AU$591.87M	16.32	15.90%	0.38%	7.76%	1.55%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMM	49 Neutral	AU$567.38M	-9.00	-35.86%	―	―	-19.21%
DXB	48 Neutral	AU$315.21M	-21.64	-83.97%	―	1271.12%	36.87%
BOT	47 Neutral	AU$226.56M	-2.56	-90.93%	―	456.50%	-457.14%
OPT	42 Neutral	AU$738.77M	-2.95	―	―	-80.08%	59.91%
OCC	41 Neutral	AU$249.60M	-26.46	-89.70%	―	42.05%	-0.84%

Botanix Pharmaceuticals Limited Corporate Events

Botanix Opens Investor Webinar to Detail Quarterly Performance and Sofdra Progress

Botanix Pharmaceuticals has opened registration for an investor webinar to be held on 27 January 2026, where senior executives will discuss the company’s Quarterly Activity Report, 4C Quarterly Cash Flow Report and provide an update on its recently approved Sofdra (sofpironium) 12.45% topical gel for primary axillary hyperhidrosis. The event underlines Botanix’s efforts to increase transparency with investors and highlight the commercial progress and strategic significance of Sofdra, which is central to the company’s positioning in the dermatology market.

The most recent analyst rating on (AU:BOT) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

Botanix Seeks ASX Quotation for 1.77 Million New Shares After Option Conversions

Botanix Pharmaceuticals Ltd has applied for quotation on the ASX of 1,771,429 new fully paid ordinary shares, following the exercise or conversion of existing options or other convertible securities. The additional shares, issued on 20 January 2026, will modestly increase the company’s free float and share capital base, potentially improving liquidity for investors and reflecting ongoing utilisation of equity-linked instruments in its capital structure.

The most recent analyst rating on (AU:BOT) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

Botanix Pharmaceuticals Cancels Shares Under Employee Scheme Buy-Back

Botanix Pharmaceuticals has cancelled 6,928,586 fully paid ordinary shares following an employee share scheme buy-back, effective 29 December 2025. The reduction in issued capital marginally tightens the company’s share base and may have implications for existing shareholders by modestly improving per-share metrics and signalling active management of its employee equity programs.

The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

Botanix Completes Final Employee Share Scheme Buy-Back

Botanix Pharmaceuticals has completed an employee share scheme buy-back of 6,928,586 ordinary fully paid shares, as disclosed in its final buy-back notification to the ASX dated 30 December 2025. The transaction, recorded with zero consideration payable, appears to be a technical or administrative cancellation of securities under an employee scheme, modestly tightening the company’s share base and potentially affecting equity allocation among existing shareholders without implying a cash outlay by the company.

The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

Botanix Details Daily Progress of Employee Share Scheme Buy-Back

Botanix Pharmaceuticals has updated the market on its ongoing employee share scheme buy-back, confirming that 6,928,586 ordinary fully paid shares were repurchased on the previous trading day, with no shares bought back before that date. The daily notification underscores the company’s active capital management via buy-backs under its employee equity arrangements, which can influence its share structure and may have implications for existing shareholders’ ownership percentages and the liquidity of BOT shares.

The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

Botanix Grants 8.75 Million Unquoted Options Under Employee Incentive Scheme

Botanix Pharmaceuticals has notified the market of the issue of 8.75 million unquoted options, each exercisable at A$0.125 and expiring on 24 December 2029, under an employee incentive scheme. The award of these unlisted options, which are not intended to be quoted on the ASX, is designed to align staff incentives with shareholder value creation and may modestly increase potential future dilution if exercised.

The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

Botanix Seeks ASX Quotation for 4.6 Million New Shares

Botanix Pharmaceuticals has applied for quotation on the ASX of 4.6 million new ordinary fully paid shares, following the issue of these securities on 18 December 2025. The additional quotation expands the company’s listed share capital, potentially enhancing liquidity in its stock and providing greater flexibility for capital management and future corporate activities.

The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

Botanix Pharmaceuticals Announces Employee Share Buy-Back

Botanix Pharmaceuticals Limited has announced a buy-back of ordinary fully paid shares under an employee share scheme. This move is part of the company’s strategy to manage its capital structure and incentivize its employees, potentially enhancing shareholder value and aligning employee interests with company goals.

The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

Botanix Pharmaceuticals Reports 2025 AGM Results with Key Resolutions Passed

Botanix Pharmaceuticals announced the results of its 2025 Annual General Meeting, where all resolutions were passed except for the approval of the Remuneration Report. The meeting included the re-election of directors and the ratification of placement shares issued to investors, indicating continued support from shareholders and strategic positioning in the market.

The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

Botanix Pharmaceuticals Reports Strong Growth Following Sofdra Launch

Botanix Pharmaceuticals Limited has successfully transitioned into a commercial revenue-generating company following the acquisition and FDA approval of its lead asset, Sofdra. The company reported significant growth in sales and revenue in its second full quarter post-launch, with a 50% increase in total prescriptions and a 65% rise in net revenue. The expansion of its sales force and the development of a differentiated fulfillment platform have been pivotal in driving this success, positioning Botanix strongly within the dermatology market.

The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.